OPN-662
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 130 patients (estimated)
- Sponsors
- Opna Bio LLC
- Tags
- Bromodomain and Extra-Terminal Protein (BET) Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1916
- NCT Identifier
- NCT06433947
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.